Ardelyx, Inc.

How big is Ardelyx, Inc.?

As of Jun 18, Ardelyx, Inc. has a market capitalization of 849.36 million, with net sales of 361.70 million and a net profit of -53.76 million over the latest four quarters. As of Dec'24, the company reported shareholder's funds of 173.29 million and total assets of 435.75 million.

Market Cap: As of Jun 18, Ardelyx, Inc. has a market capitalization of 849.36 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Ardelyx, Inc. reported net sales of 361.70 million and a net profit of -53.76 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 173.29 million and total assets of 435.75 million.

What does Ardelyx, Inc. do?

Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cardiorenal and gastrointestinal diseases. As of March 2025, it reported net sales of $74 million and a net loss of $41 million, with a market cap of approximately $849.36 million.

Overview:<BR>Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cardiorenal and gastrointestinal diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 74 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -41 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 849.36 Million (Small Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.42 <BR>Return on Equity: -36.79% <BR>Price to Book: 5.83<BR><BR>Contact Details:<BR>Address: 34175 Ardenwood Blvd, FREMONT CA: 94555-3653 <BR>Tel: 1 510 7457047 <BR>Fax: 1 510 7450493 <BR>Website: https://www.ardelyx.com/

Who are in the management team of Ardelyx, Inc.?

As of March 2022, the management team of Ardelyx, Inc. includes Independent Chairman David Mott, CEO Michael Raab, and several Independent Directors: Robert Bazemore, William Bertrand, Geoffrey Block, Onaiza Cadoret-Manier, and Jan Lundberg. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Ardelyx, Inc. includes the following individuals:<BR><BR>- Mr. David Mott, who serves as the Independent Chairman of the Board.<BR>- Mr. Michael Raab, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Robert Bazemore, who is an Independent Director.<BR>- Mr. William Bertrand, who is also an Independent Director.<BR>- Dr. Geoffrey Block, serving as an Independent Director.<BR>- Ms. Onaiza Cadoret-Manier, who is an Independent Director.<BR>- Dr. Jan Lundberg, who is another Independent Director.<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Should I buy, sell or hold Ardelyx, Inc.?

Is Ardelyx, Inc. overvalued or undervalued?

As of November 6, 2019, Ardelyx, Inc. is considered risky and appears overvalued due to negative profitability indicators and high valuation ratios compared to peers, despite a strong 3-year return of 390.08% and recent volatility.

As of 6 November 2019, the valuation grade for Ardelyx, Inc. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. Based on the available metrics, Ardelyx appears to be overvalued, particularly given its negative profitability indicators. The company has a Price to Book Value of 6.04, an EV to EBIT of -20.67, and an EV to EBITDA of -21.91, all of which suggest that the stock is trading at a premium despite its losses.<BR><BR>In comparison to peers, Ardelyx's valuation ratios are concerning; for instance, Ligand Pharmaceuticals, Inc. has a P/E of -67.27 and an EV to EBITDA of 132.07, while MannKind Corp. shows a P/E of 38.35 and an EV to EBITDA of 18.98, indicating that Ardelyx is not competitively positioned within its industry. Furthermore, while Ardelyx has shown a strong 3-year return of 390.08%, this is contrasted by a recent 1-week decline of -3.89% against the S&P 500's 1.05% gain, highlighting volatility and potential overvaluation concerns.

Is Ardelyx, Inc. technically bullish or bearish?

As of September 9, 2025, Ardelyx, Inc. has a bullish trend supported by positive indicators, despite a bearish weekly RSI, with a 10.50% return over the past month and a remarkable 390.08% return over the past three years compared to the S&P 500's 2.33% and 70.41%, respectively.

As of 9 September 2025, the technical trend for Ardelyx, Inc. has changed from mildly bullish to bullish. The current stance is bullish, with key indicators supporting this position including a bullish MACD on the weekly timeframe, bullish moving averages on the daily timeframe, and a bullish OBV on both weekly and monthly timeframes. However, the weekly RSI is bearish, which indicates some short-term weakness. <BR><BR>In terms of performance, Ardelyx has shown a 10.50% return over the past month compared to the S&P 500's 2.33%, and a significant 390.08% return over the past three years against the S&P 500's 70.41%.